Project title: Developing nanodrugs delivery system to enhance the therapeutic effects on brain cancer
Program title: Developing nanodrugs delivery system to enhance the therapeutic effects on brain cancer
Overcome the Temozolomide-resistant human glioblastomas cells: From clinical to bench
Dueng-Yuan Hueng 1,2,3, I-Ping Wu2, Li-Chung Huang2, Hsin-Ying Clair Chiou4, Jen-Kun Chen5, Chung-Shi Yang5
1Department of Neurological Surgery, Tri-Service General Hospital, 2Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, 3Superintendent Office, Penghu Branch of Tri-Service General Hospital, National Defense Medical Center, Magong City, Penghu County, Taiwan, 4Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Institute of Biomedical Engineering and Nanomedicine, National Health Research Institute, Taiwan
Human glioblastomas are characterized with high mortality due to the resistance to clinical standard therapeutic practice. The purpose of this study is to characterize the Temozolomide-resistant (TMZ-R) and -sensitive (TMZ-S) clones for translational study. Our study found that high expression of methylguanine methyltransferase (MGMT) contributed to high mortality. Moreover, TMZ-resistant clone highly expressed MGMT. We further characterize the gene expression profile between TMZ-R and TMZ-S clones using gene array. Next, we found novel method to re-sensitize the TMZ-R human glioblastomas. Taken together, our findings provide the future clinical trial perspectives in improvement of survival of human glioblastomas.